Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  AbbVie    ABBV

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Research Results from AbbVie Update Understanding of Medicinal Chemistry (Beyond the Rule of 5: Lessons Learned from AbbVie's Drugs and Compound...

share with twitter share with LinkedIn share with facebook
share via e-mail
10/05/2017 | 05:58pm CET

Research Results from AbbVie Update Understanding of Medicinal Chemistry (Beyond the Rule of 5: Lessons Learned from AbbVie's Drugs and Compound Collection)

By a News Reporter-Staff News Editor at Drug Week -- New research on Health and Medicine - Medicinal Chemistry is the subject of a report. According to news reporting originating from North Chicago, Illinois, by NewsRx correspondents, research stated, "Recently, there has been an increasing focus on the pursuit of targets considered to be less druggable that offer potential for development of promising new therapeutic agents for the treatment of diseases with large unmet medical need, particularly in the areas of oncology and virology. However, conducting drug discovery campaigns in 'beyond rule of 5' (bRo5) chemical space presents a significant drug design and development challenge to medicinal chemists to achieve acceptable oral pharmacokinetics."

Our news editors obtained a quote from the research from AbbVie, "Retrospective analysis of past successes and failures in drug discovery bRo5 may shed light on the key principles that contribute to the oral bioavailability of successful bRo5 compounds and improve the efficiency of drug design for future projects. We present here highlights and case studies of lessons learned from discovery of bRo5 compounds."

According to the news editors, the research concluded: "A simple multiparametric scoring function (AB-MPS) was devised that correlated preclinical PK results with cLogD, number of rotatable bonds, and number of aromatic rings."

For more information on this research see: Beyond the Rule of 5: Lessons Learned from AbbVie's Drugs and Compound Collection. Journal of Medicinal Chemistry, 2017;():. (American Chemical Society - www.acs.org; Journal of Medicinal Chemistry - www.pubs.acs.org/journal/jmcmar)

The news editors report that additional information may be obtained by contacting D.A. DeGoey, Research and Development, AbbVie Inc , 1 North Waukegan Road, North Chicago, Illinois 60064, United States. Additional authors for this research include H.J. Chen, P.B. Cox and M.D Wendt (see also Health and Medicine - Medicinal Chemistry).

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1021/acs.jmedchem.7b00717. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Keywords for this news article include: Illinois, North Chicago, United States, Drugs and Therapies, Health and Medicine, Medicinal Chemistry, North and Central America.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

(c) 2017 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ABBVIE
11:59a ABBVIE : A new role for Bcl-XL in fibrosis
12:05a Wall Street falls as investors fret about tax bill passage
12/14 ABBVIE : Recent Data from A.J. Epstein and Co-Authors Highlight Findings in Endo..
12/14 ABBVIE : New Molecular Pharmaceutics Findings from AbbVie Discussed (Impact of P..
12/14 ABBVIE : IMBRUVICA Data Provide Insights Into Its Potential Treatment Benefits
12/14 ABBVIE : Announces Phase 3 Study of VENCLEXTA VENCLYXTO in Combination with Ritu..
12/13 ABBVIE : Roche boast stellar PhIII leukemia data for a breakthrough combo with b..
12/12 ABBVIE : IMBRUVICA Pooled Analysis Suggests Benefit in Progression-Free Survival..
12/12 ABBVIE : IMBRUVICA Patient-Reported Outcomes Data Detail Long-Term Improvement i..
12/12 ABBVIE : Announces Phase 3 Study of VENCLEXTA™/ VENCLYXTO™ (venetocl..
More news
News from SeekingAlpha
12/14 More Positives For Roche, The Core Biotech For The Long Run
12/14 BIOTECH ANALYSIS CENTRAL PHARMA NEWS : AbbVie And Roche Stellar Data, Aduro Pull..
12/13 ARGENX : This ASH Winner Has Further Upside Ahead
12/13 3 THINGS IN BIOTECH YOU SHOULD LEARN : December 13, 2017
12/13 Why Tech Still Looks So Attractive
Financials ($)
Sales 2017 27 998 M
EBIT 2017 11 955 M
Net income 2017 7 316 M
Debt 2017 26 790 M
Yield 2017 2,70%
P/E ratio 2017 20,76
P/E ratio 2018 16,37
EV / Sales 2017 6,44x
EV / Sales 2018 5,70x
Capitalization 154 B
Duration : Period :
AbbVie Technical Analysis Chart | ABBV | US00287Y1091 | 4-Traders
Technical analysis trends ABBVIE
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 100 $
Spread / Average Target 4,2%
EPS Revisions
Richard A. Gonzalez Chairman & Chief Executive Officer
Azita Saleki-Gerhardt Senior Vice President-Operations
William J. Chase Chief Financial Officer & Executive Vice President
Michael E. Severino Chief Scientific Officer & Executive VP
Robert J. Alpern Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ABBVIE55.46%153 511
MERCK KGAA-9.18%13 715
CONVATEC GROUP-13.13%5 322